Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Pharmacokinetic data
Elimination half-life 7-27 hours
CAS Number
PubChem CID
Chemical and physical data
Formula C20H25NO2
Molar mass 311.42 g/mol
3D model (JSmol)

Femoxetine (INN) (tentative brand name Malexil; developmental code name FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It acts as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.

Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though).[1][2] Jorgen Buus-Lassen's name is on the pharmacology paper though.[3]

After Ferrosan's acquisition, femoxetine died from neglect.[4]

Addition of the para-fluoro atom results in a different compound that is a hybrid of femoxetine & paroxetine named FG 7080, which has a separate patent.[5] According to the patent tables, incorporation of the fluorine atom potentiated the 5-HT affinity considerably.

See also


  1. U.S. Patent 3,912,743
  2. U.S. Patent 4,007,196
  3. Lassen, Jørgen Buus; Petersen, Erling; Kjellberg, Bengt; Olsson, Sven O. (1975). "Comparative studies of a new 5HT-uptake inhibitor and some tricyclic thymoleptics". European Journal of Pharmacology. 32 (1): 108–115. doi:10.1016/0014-2999(75)90329-5. ISSN 0014-2999.
  4. Healy, David (2004). Let them eat Prozac : the unhealthy relationship between the pharmaceutical industry and depression. New York, NY: New York Univ. Press. pp. 26–27. ISBN 9780814736692.
  5. U.S. Patent 4,585,777

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.